Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): A systematic review. 2017

Sarah R Hoffman, and Tam Le, and Alexandre Lockhart, and Ayodeji Sanusi, and Leila Dal Santo, and Meagan Davis, and Dana A McKinney, and Meagan Brown, and Charles Poole, and Corinne Willame, and Jennifer S Smith
Department of Epidemiology, UNC Gillings School of Global Public Health, Chapel Hill, NC.

A systematic review of the literature was conducted to determine the estimates of and definitions for human papillomavirus (HPV) persistence in women following treatment of cervical intra-epithelial neoplasia (CIN). A total of 45 studies presented data on post-treatment HPV persistence among 6,106 women. Most studies assessed HPV persistence after loop excision (42%), followed by conization (7%), cryotherapy (11%), laser treatment (4%), interferon-alpha, therapeutic vaccination, and photodynamic therapy (2% each) and mixed treatment (38%). Baseline HPV testing was conducted before or at treatment for most studies (96%). Follow-up HPV testing ranged from 1.5 to 80 months after baseline. Median HPV persistence tended to decrease with increasing follow-up time, declining from 27% at 3 months after treatment to 21% at 6 months, 15% at 12 months, and 10% at 24 months. Post-treatment HPV persistence estimates varied widely and were influenced by patient age, HPV-type, detection method, treatment method, and minimum HPV post-treatment testing interval. Loop excision and conization appeared to outperform cryotherapy procedures in terms of their ability to clear HPV infection. This systematic review provides evidence for the substantial heterogeneity in post-treatment HPV DNA testing practices and persistence estimates.

UI MeSH Term Description Entries
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D010778 Photochemotherapy Therapy using oral or topical photosensitizing agents with subsequent exposure to light. Blue Light Photodynamic Therapy,Photodynamic Therapy,Red Light PDT,Red Light Photodynamic Therapy,Therapy, Photodynamic,Light PDT, Red,PDT, Red Light,Photochemotherapies,Photodynamic Therapies,Therapies, Photodynamic
D002578 Uterine Cervical Dysplasia Abnormal development of immature squamous EPITHELIAL CELLS of the UTERINE CERVIX, a term used to describe premalignant cytological changes in the cervical EPITHELIUM. These atypical cells do not penetrate the epithelial BASEMENT MEMBRANE. Cervical Dysplasia,Cervical Intraepithelial Neoplasia,Cervix Dysplasia,Dysplasia of Cervix Uteri,Neoplasia, Cervical Intraepithelial,Cervical Intraepithelial Neoplasia, Grade III,Cervical Intraepithelial Neoplasms,Intraepithelial Neoplasia, Cervical,Cervical Dysplasia, Uterine,Cervical Dysplasias,Cervical Intraepithelial Neoplasm,Cervix Uteri Dysplasia,Cervix Uteri Dysplasias,Dysplasia, Cervical,Dysplasia, Cervix,Dysplasia, Uterine Cervical,Intraepithelial Neoplasm, Cervical,Intraepithelial Neoplasms, Cervical,Neoplasm, Cervical Intraepithelial,Neoplasms, Cervical Intraepithelial
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D061809 Human Papillomavirus DNA Tests Methods for detecting or typing the DNA of an ALPHAPAPILLOMAVIRUS in biological tissues and fluids. HPV DNA Test,Human Papillomavirus DNA Test,HPV DNA Tests,DNA Test, HPV,DNA Tests, HPV,Test, HPV DNA,Tests, HPV DNA
D027383 Papillomaviridae A family of small, non-enveloped DNA viruses infecting birds and most mammals, especially humans. They are grouped into multiple genera, but the viruses are highly host-species specific and tissue-restricted. They are commonly divided into hundreds of papillomavirus "types", each with specific gene function and gene control regions, despite sequence homology. Human papillomaviruses are found in the genera ALPHAPAPILLOMAVIRUS; BETAPAPILLOMAVIRUS; GAMMAPAPILLOMAVIRUS; and MUPAPILLOMAVIRUS.
D030361 Papillomavirus Infections Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression. HPV Infection,Human Papillomavirus Infection,HPV Infections,Human Papillomavirus Infections,Papillomavirus Infection,Papillomavirus Infection, Human,Papillomavirus Infections, Human

Related Publications

Sarah R Hoffman, and Tam Le, and Alexandre Lockhart, and Ayodeji Sanusi, and Leila Dal Santo, and Meagan Davis, and Dana A McKinney, and Meagan Brown, and Charles Poole, and Corinne Willame, and Jennifer S Smith
May 2023, BMC women's health,
Sarah R Hoffman, and Tam Le, and Alexandre Lockhart, and Ayodeji Sanusi, and Leila Dal Santo, and Meagan Davis, and Dana A McKinney, and Meagan Brown, and Charles Poole, and Corinne Willame, and Jennifer S Smith
January 1997, Minerva ginecologica,
Sarah R Hoffman, and Tam Le, and Alexandre Lockhart, and Ayodeji Sanusi, and Leila Dal Santo, and Meagan Davis, and Dana A McKinney, and Meagan Brown, and Charles Poole, and Corinne Willame, and Jennifer S Smith
November 1988, Cancer,
Sarah R Hoffman, and Tam Le, and Alexandre Lockhart, and Ayodeji Sanusi, and Leila Dal Santo, and Meagan Davis, and Dana A McKinney, and Meagan Brown, and Charles Poole, and Corinne Willame, and Jennifer S Smith
July 2000, Sao Paulo medical journal = Revista paulista de medicina,
Sarah R Hoffman, and Tam Le, and Alexandre Lockhart, and Ayodeji Sanusi, and Leila Dal Santo, and Meagan Davis, and Dana A McKinney, and Meagan Brown, and Charles Poole, and Corinne Willame, and Jennifer S Smith
January 1990, Zentralblatt fur Gynakologie,
Sarah R Hoffman, and Tam Le, and Alexandre Lockhart, and Ayodeji Sanusi, and Leila Dal Santo, and Meagan Davis, and Dana A McKinney, and Meagan Brown, and Charles Poole, and Corinne Willame, and Jennifer S Smith
January 1998, European journal of gynaecological oncology,
Sarah R Hoffman, and Tam Le, and Alexandre Lockhart, and Ayodeji Sanusi, and Leila Dal Santo, and Meagan Davis, and Dana A McKinney, and Meagan Brown, and Charles Poole, and Corinne Willame, and Jennifer S Smith
March 2002, International journal of cancer,
Sarah R Hoffman, and Tam Le, and Alexandre Lockhart, and Ayodeji Sanusi, and Leila Dal Santo, and Meagan Davis, and Dana A McKinney, and Meagan Brown, and Charles Poole, and Corinne Willame, and Jennifer S Smith
July 1997, Obstetrics and gynecology,
Sarah R Hoffman, and Tam Le, and Alexandre Lockhart, and Ayodeji Sanusi, and Leila Dal Santo, and Meagan Davis, and Dana A McKinney, and Meagan Brown, and Charles Poole, and Corinne Willame, and Jennifer S Smith
March 1997, Obstetrics and gynecology,
Sarah R Hoffman, and Tam Le, and Alexandre Lockhart, and Ayodeji Sanusi, and Leila Dal Santo, and Meagan Davis, and Dana A McKinney, and Meagan Brown, and Charles Poole, and Corinne Willame, and Jennifer S Smith
March 2011, Gynecologic oncology,
Copied contents to your clipboard!